XTENT Announces 2007 Financial Results(December 31 ...),Health

2007 2006 2007 2006

Operating expenses:

Research and development (1) $9,194 $5,520 $30,888 $18,923

General and administrative (1) 3,375 1,981 11,269 7,258

Total operating expenses 12,569 7,501 42,157 26,181

Loss from operations (12,569) (7,501) (42,157) (26,181)

Interest and other income, net 705 336 3,363 1,137

Net loss (11,864) (7,165) (38,794) (25,044)

Deemed dividend related to

beneficial conversion feature of

redeemable convertible preferred

stock - - - (13,095)

Net loss attributable to common

stockholders $(11,864) $(7,165) $(38,794) $(38,139)

Net loss per share attributable to

common stockholders - basic and

diluted $(0.52) $(2.46) $(1.87) $(13.96)

Weighted-average common shares

outstanding used in per share

calculation 22,790 2,909 20,703 2,732

(1) Includes the following stock-

based compensation charges:

Research and development $460 $408 $1,490 $1,258

General and administrative $766 $408 $2,088 $986

XTENT, INC.

(a development stage company)

Condensed Balance Sheets

(unaudited, in thousands)

December 31, December 31,

2007 2006

Cash and cash equivalents and short

term investments $57,760 $23,105

Working capital
'/>"/>